Shares Magazine
$164.10+0.60 (+0.37%)28 Mar 2025, 19:05
Jump to:
Johnson & Johnson Fundamentals
| Company Name | Johnson & Johnson | Last Updated | 2025-03-28 |
|---|---|---|---|
| Industry | Drug Manufacturers - General | Sector | Healthcare |
| Shares in Issue | 2.410 bn | Market Cap | $395.46 bn |
| PE Ratio | 28.34 | Dividend per Share | $4.91 |
| Dividend Yield | 3.02 | Dividend Cover | 1.18 |
| EPS | $5.79 | EPS Growth (%) | -0.01 |
| PEG | 1.11 | DPS Growth (%) | 0.0447 |
| Debt Ratio | 0.2034 | Debt Equity Ratio | 0.4287 |
| Asset Equity Ratio | 2.5193 | Cash Equity Ratio | 0.3430 |
| Quick Ratio | 0.8634 | Current Ratio | 1.11 |
| Price To Book Value | 5.5310 | ROCE | 0 |
Johnson & Johnson Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|---|---|---|---|---|
| Interim | 2025-02-18 | 2025-03-04 | USD | 1.2400 | |
| Prelim | 2024-11-26 | 2024-12-10 | USD | 1.2400 | |
| Interim | 2024-08-27 | 2024-09-10 | USD | 1.2400 | |
| Prelim | 2024-05-20 | 2024-06-04 | USD | 1.2400 | |
| Prelim | 2024-02-16 | 2024-03-05 | USD | 1.1900 | |
| Prelim | 2023-11-20 | 2023-12-05 | USD | 1.1900 | |
| Interim | 2023-08-25 | 2023-09-07 | USD | 1.1900 | |
| Interim | 2023-05-22 | 2023-06-06 | USD | 1.1900 | |
| Interim | 2023-02-17 | 2023-03-07 | USD | 1.1300 | |
| Prelim | 2022-11-21 | 2022-12-06 | USD | 1.1300 | |
| Interim | 2022-08-22 | 2022-09-06 | USD | 1.1300 | |
| Interim | 2022-05-23 | 2022-06-07 | USD | 1.1300 |
Johnson & Johnson Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | $20.52 bn | $19.90 bn | $17.98 bn |
| Intangible Assets | $81.82 bn | $70.73 bn | $74.54 bn |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | $124.21 bn | $114.06 bn | $132.08 bn |
| Stocks | $12.44 bn | $11.18 bn | $10.27 bn |
| Debtors | 0 | 0 | 0 |
| Cash & Equivalents | $24.52 bn | $22.93 bn | $22.28 bn |
| Other Assets | 0 | 0 | 0 |
| Total Assets | $180.10 bn | $167.56 bn | $187.38 bn |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | $50.32 bn | $46.28 bn | $55.80 bn |
| Creditors after 1 year | $58.29 bn | $52.50 bn | $54.77 bn |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $108.61 bn | $98.78 bn | $110.57 bn |
| Net assets | $71.49 bn | $68.77 bn | $76.80 bn |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | $3.12 bn | $3.12 bn | $3.12 bn |
| Share Premium | $155.79 bn | $153.84 bn | $128.34 bn |
| Profit / Loss | $16.69 bn | $15.06 bn | $19.36 bn |
| Other Equity | $71.49 bn | $68.77 bn | $76.80 bn |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | $71.49 bn | $68.77 bn | $76.80 bn |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | $0.30 | $0.27 | $0.26 |
| Debt-to-Equity | $0.43 | $0.38 | $0.35 |
| Assets / Equity | 2.5193 | 2.5193 | 2.5193 |
| Cash / Equity | 0.3430 | 0.3430 | 0.3430 |
| EPS | $8.34 | $8.40 | $6.57 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | $24.27 bn | $22.79 bn | $21.19 bn |
| Cashflow before financing | $21.13 bn | $6.97 bn | $12.32 bn |
| Increase in Cash | $2.25 bn | $7.73 bn | -$360.00 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | $88.82 bn | $85.16 bn | $79.99 bn |
| Cost of sales | $27.47 bn | $26.55 bn | $24.60 bn |
| Gross Profit | $61.35 bn | $58.61 bn | $55.39 bn |
| Operating Profit | 0 | 0 | 0 |
| Pre-Tax profit | $16.69 bn | $15.06 bn | $19.36 bn |
Johnson & Johnson Company Background
| Sector | Healthcare |
|---|---|
| Activities | Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States. |
| Latest Interim Date | 17 Jul 2024 |
| Latest Fiscal Year End Date | 22 Jan 2025 |
Johnson & Johnson Directors
| Appointed | Name | Position |
|---|---|---|
| 2023-01-17 | Mr. Alex Gorsky | Director |
| 2010-03-09 | Mr. Arnold G. Langbo | Director |
| 2004-09-03 | Brian D. Perkins | |
| 2024-04-25 | Ms. Anne M. Mulcahy | Director |
| 2013-02-11 | Dr. David Satcher,M.D.,PhD | Director |
| 2022-02-15 | Mr. Charles O. Prince, III | Director |
| 2024-04-25 | Mr. D. Scott Davis | Director |
| 2018-02-12 | Mr. Dominic J. Caruso | Exec VP, Finance; CFO |
| 2009-09-10 | Mr. Donald M. Casey, Jr | Member, Executive Committee |
| 2005-04-28 | Mr. Gerard N. Burrow | Director |
| 2005-04-28 | Mr. Henry B Schacht | Director |
| 2025-02-15 | Dr. John C. Reed,M.D.,PhD | EVP, Innovative Medicine, R&D |
| 2005-12-30 | Ms. Joann Heffernan Heisen | VP, Chief Information Officer |
| 2005-04-28 | Mr. M. Judah Folkman,M.D. | Director |
| 2009-12-31 | Ms. Kaye I. Foster-Cheek | VP, Human Resources |
| 2015-02-09 | Mr. Leo F. Mullin | Director |
| 2025-03-04 | Ms. Marillyn A. Hewson | Director |
| 2016-02-08 | Dr. Mary Sue Coleman, PhD | Director |
| 2006-10-24 | Mr. Michael J. Dormer | Member, Executive Committee |
| 2014-02-10 | Dr. Michael M. E. Johns,M.D. | Director |
| 2022-02-14 | Dr. Mathai Mammen, M.D.,PhD | EVP, Pharm, R&D |
| 2007-02-16 | Dr. Per A. Peterson,PhD | Executive Committee Member |
| 2009-09-30 | Mr. Nicholas J. Valeriani | |
| 2022-02-15 | Mr. Ronald A. Williams | Director |
| 2018-02-12 | Ms. Sandra E. Peterson | Exec VP, Group WW Chairman |
| 2007-02-16 | Mr. Robert J. Darretta,Jr | Director, Vice Chairman |
| 2004-08-31 | Fine Roger S | |
| 2012-02-22 | Mr. Russell C. Deyo | VP, General Counsel |
| 2012-02-09 | Ms. Sherilyn S. McCoy | Member, Executive Committee |
| 2015-02-09 | Mr. Stephen J. Cosgrove | Corporate Controller |
| 2016-09-06 | Dr. Susan L. Lindquist,PhD | Director |
| 2007-03-13 | Ms. Ann Dibble Jordan | Director |
| 2011-01-10 | Ms. Colleen A. Goggins | Member, Executive Committee |
| 2013-02-08 | Mr. William C Weldon | |
| 2009-02-12 | Ms. Christine A. Poon | Director, Vice Chairman |
| 2015-02-09 | Mr. James G. Cullen | Director |
| 2004-06-30 | Mr. James T. Lenehan | |
| 2008-05-28 | Mr. Joseph C. Scodari | |
| 2024-04-25 | Dr. Paula A. Johnson,M.D. | Director |
| 2008-03-11 | Mr. Steven S. Reinemund | Director |
| 2020-03-13 | Mr. William D. Perez | Director |
| 2024-04-25 | Mr. Hubert Joly | Director |
| 2022-02-15 | Mr. Ian Edward Lamert Davis | Director |
| 2024-02-15 | Dr. Peter M. Fasolo, PhD | Exec VP, Chief HR Officer |
| 2024-04-25 | Dr. Mary C. Beckerle, PhD | Director |
| 2024-04-25 | Mr. Darius E. Adamczyk | Director |
| 2022-02-14 | Mr. Michael H. Ullmann | Exec VP, General Counsel |
| 2019-02-08 | Mr. Jorge S. Mesquita | Exec VP, WW Chair, Consumer |
| 2021-02-12 | Dr. Paulus Stoffels | Vice Chair, Exec Committee |
| 2023-03-07 | Dr. A. Eugene Washington, M.D. | Director |
| 2024-04-25 | Dr. Mark B. McClellan, M.D.,PhD | Director |
| 2019-02-08 | Mr. Ronald A. Kapusta | Controller, CAO |
| 2025-03-18 | Mr. Joaquin Duato | Director, CEO and Chairman of the Board |
| 2017-02-28 | Mr. Gary John Pruden | Exec VP, WW Chair, Med Devices |
| 2024-04-25 | Dr. Jennifer A. Doudna, PhD | Director |
| 2025-02-15 | Mr. Joseph J. Wolk, C.P.A. | Exec VP, CFO |
| 2025-02-15 | Mr. James D. Swanson | EVP, CIO |
| 2023-08-23 | Ms. Ashley McEvoy | EVP, WW Chair, MedTech |
| 2025-02-15 | Ms. Jennifer L. Taubert | EVP, WWC. Innovative Medicine |
| 2025-02-15 | Ms. Kathryn E. Wengel | EVP, Chief TO and Risk Officer |
| 2021-02-12 | Mr. Michael E. Sneed | EVP, Global Corp Aff & CCO |
| 2025-03-04 | Mr. Eugene A. Woods | Director |
| 2023-02-13 | Mr. Thibaut Mongon | Exec VP, WW Chair, Cons Health |
| 2024-04-25 | Dr. Nadja Y. West, M.D. | Director |
| 2024-12-12 | Mr. Mark A. Weinberger | Director |
| 2025-02-25 | Mr. Robert J. Decker, Jr | VP Corporate Controller |
| 2024-02-15 | Mr. William N. Hait, M.D.,PhD | EVP, Chief EI and Med Officer |
| 2025-02-15 | Ms. Vanessa Broadhurst | EVP, Global Corp Affairs |
| 2025-02-15 | Ms. Elizabeth Forminard | Executive VP, General Counsel |
| 2025-02-15 | Mr. Timothy Schmid | EVP, WW Chair, MedTech |
| 2025-02-15 | Ms. Kristen Mulholland | EVP, Chief HR Officer |
Johnson & Johnson Contact Details
| Company Name | Johnson & Johnson |
|---|---|
| Address | One Johnson and Johnson Plaza, New Brunswick, 08933 |
| Telephone | +1 781 5752718 |
| Website | https://www.jnj.com |
Johnson & Johnson Advisors
| Auditor | PricewaterhouseCoopers LLP |
|---|---|
| Phone | +1 973 410-7600 |
| Fax | +1 973 410-7676 |
| Auditor | PricewaterhouseCoopers |
|---|---|
| Phone | +1 441 295-2000 |
| Fax | +1 441 295-1242 |
| Auditor | Coopers & Lybrand |
|---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Sse PLC | 1,606.00 | 3.85 |
| Spire Healthcare Group PLC | 178.60 | 3.84 |
| British Land Company PLC | 374.40 | 3.43 |
| B&M European Value Retail S.A. | 269.90 | 3.37 |
| Supermarket Income Reit PLC | 77.50 | 3.20 |
| National Grid PLC | 1,009.50 | 2.86 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Close Brothers Group PLC | 299.80 | -9.37 |
| Trustpilot Group PLC | 233.50 | -6.79 |
| Wizz Air Holdings PLC | 1,575.00 | -5.41 |
| Aston Martin Lagonda Global Holdings PLC | 65.25 | -5.02 |
| Wh Smith PLC | 1,039.00 | -4.68 |
| Melrose Industries PLC | 492.70 | -4.63 |
Risers/fallers data from previous trading day.